Distinguished in Multiple Myeloma

Dr. Henry K. Holland

Blood And Marrow Transplant Group Of Georgia
Atlanta, GA
Distinguished
in Multiple Myeloma
Specialties:Hematology | Oncology
Accepting New Patients
Offers Telehealth
43 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Henry Holland is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Holland has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Acute Myeloid Leukemia (AML), Childhood Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Holland is currently accepting new patients.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 1 clinical trial in the study of Multiple Myeloma.

Graduate Year
1982
Specialties
Hematology
Oncology
Licenses
Specialist in GA
Hospital Affiliations
Northside Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Alliant Health
  •  CareSource
  •  Humana

Locations

BLOOD AND MARROW TRANSPLANT GROUP OF GEORGIA
5670 Peachtree Dunwoody Rd Ne, Suite 1000, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: Rituximab, Ibrutinib
Study Phase: Phase 2
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: Fludarabine, Melphalan, Pembrolizumab
Study Phase: Phase 2
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Enrollment Status: Terminated
Publish Date: November 14, 2022
Intervention Type: Biological
Study Drug: Anti-COVID-19 Plasma
Study Phase: Phase 2
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: September 02, 2021
Intervention Type: Drug
Study Drug: MLN9708
Study Phase: Phase 2
A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy
A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy
Enrollment Status: Completed
Publish Date: April 17, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

43 Total Publications

Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation.
Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation.
Journal: Transplantation and cellular therapy
Published: April 08, 2024
Similar Doctors
Expertise in
18
conditions
Dr. Sagar Lonial
Hematology | Oncology
Expertise in
18
conditions
Dr. Sagar Lonial
Hematology | Oncology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (8.3 mi)
404-778-7525
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sagar Lonial is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Lonial and is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Transplant. Dr. Lonial is currently accepting new patients.

Expertise in
15
conditions
Dr. Craig C. Hofmeister
Hematology | Hematology Oncology
Expertise in
15
conditions
Dr. Craig C. Hofmeister
Hematology | Hematology Oncology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (8.3 mi)
404-778-7525
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Hofmeister is a Hematologist and a Hematologist Oncology provider in Atlanta, Georgia. Dr. Hofmeister and is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hofmeister is currently accepting new patients.

Expertise in
17
conditions
Dr. Ajay K. Nooka
Hematology Oncology | Transplant Surgery | Hematology
Expertise in
17
conditions
Dr. Ajay K. Nooka
Hematology Oncology | Transplant Surgery | Hematology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (8.3 mi)
404-778-7525
Languages Spoken:
English, Hindi, Spanish, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajay Nooka is a Hematologist Oncology specialist and a Transplant Surgeon in Atlanta, Georgia. Dr. Nooka and is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Nooka is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile